| dc.contributor.advisor | najafipur, Farzin | |
| dc.contributor.author | javanshir, Parisa | |
| dc.date.accessioned | 2020-08-09T09:18:50Z | |
| dc.date.available | 2020-08-09T09:18:50Z | |
| dc.date.issued | 2020 | en_US |
| dc.identifier.uri | http://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/62288 | |
| dc.description.abstract | Insulin therapy is the best treatment in patients with type 2 Diabets who have suffered a failure with Blood suger However, the exogen insulin such as endogen insulin is not able toset the exact blood suger and it causes the limits of the use of
Materials and Methods:
A group was treated with DPP4inhibitor(sitagiliptin) and the second group received placebo and blood suger at the beginning of study and 3 monthes after treatment
Results:
In this study, 30 people recived insulin and sitagliptin for 3 months and 30 people received insulin only. In the group that received sitagiliptin don’t see the meanful change to weight, blood suger and HbA1C | en_US |
| dc.language.iso | fa | en_US |
| dc.publisher | Tabriz University of Medical Sciences, Faculty of Medicine | en_US |
| dc.subject | type 2 diabetes | en_US |
| dc.subject | DPP4 inhibitor | en_US |
| dc.subject | Insulin | en_US |
| dc.title | Study of glycemic and weight control in type 2 diabets patients treated with variable insulin regimens addition of DPP4 inhibitor | en_US |
| dc.type | Thesis | en_US |
| dc.contributor.supervisor | sadra, Vahid | |
| dc.identifier.docno | 609564 | en_US |
| dc.identifier.callno | 9564 | en_US |
| dc.description.discipline | Medicine | en_US |
| dc.description.degree | M. D degree | en_US |
